Ionis Pharmaceuticals is a biotechnology company that develops RNA-targeted medicines. It lobbies on health and drug policy, focusing on Medicare and Medicaid rules, tax laws like the Internal Revenue Code and the Inflation Reduction Act’s implementation, and bills affecting orphan drugs and incentives for new drug innovation. Its filings show in‑house lobbying and about $460,000 reported through early 2026.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
JORDAN CHAPMAN
The latest disclosures for this client.
IONIS PHARMACEUTICALS, INC.
Q1IONIS PHARMACEUTICALS, INC.
Q4The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
IONIS PHARMACEUTICALS, INC.
IONIS PHARMACEUTICALS, INC.
Q3IONIS PHARMACEUTICALS, INC.
Q2IONIS PHARMACEUTICALS, INC.
Q1